Fortress Biotech (FBIO) said Wednesday that it has agreed to sell 16.6 million common shares at $0.835 apiece in a registered direct offering to raise...
Fortress Biotech (FBIO) subsidiary Urica Therapeutics said Wednesday it has expanded its gout drug development license agreement with Fuji Yakuhin to...
Fortress Biotech (FBIO) reported Monday a Q3 non-GAAP loss of $0.08 per share, compared with earnings of $0.60 per share a year earlier. One analyst...
...
| Address | 1111 Kane Concourse Bay Harbor Islands, Florida 33154 |
| Phone | +1.781.652.4500 |
| Number of Employees | 88 |
| Recent SEC Filing | 01/13/2023 SC 13D/A |
| Chairman, President & Chief Executive Officer | Lindsay Allan Rosenwald |
| CFO & Head-Corporate Development | David Jin |
| Senior Vice President-Biologics Operations | George C. Avgerinos |
| Director & Vice Chairman-Strategic Development | Michael Sean Weiss |
| Price Open | $0.71 |
| Previous Close | $0.84 |
| 52 Week Range | $0.48 - 2.10 |
| Market Capitalization | $81.3 M |
| Shares Outstanding | 107.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 03/27/2023 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.98 |
| Beta vs. S&P 500 | N/A |
| Revenue | $26.9 M |
| Net Profit Margin | -117.49% |
| Return on Equity | -105.60% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
